Pre-existing anti-AAV antibodies can be detected using ligand binding-based assay formats. One such format is the MSD-based bridging assay, which uses sulfo-tag-labeled AAV vectors as detection reagents. However, no method has been developed to accurately measure the degree of sulfo-tag labeling on AAV vectors. To fill this gap, we developed a liquid chromatography-high resolution mass spectrometry (LC-HRMS) method to assess the degree of labeling (DoL) of sulfo-tag on AAV5 vectors, enabling the measurement of the DoL on AAV5 at six increasing levels of sulfo-tag challenge ratio. In addition, a Biacore-based assay was used to evaluate the binding affinity between an anti-AAV5 monoclonal antibody and various sulfo-tag labeled AAV5 vectors. The results indicated that increased DoL of sulfo-tag labeling on AAV5 did not compromise the binding affinity.Our study further employed the MSD-bridging assay to detect the binding Signal/Noise (S/N) ratios of four anti-AAV5 monoclonal antibodies (mAbs) to various sulfo-tag-labeled AAV5 vectors. The findings revealed a strong correlation between the degree of sulfo-tag labeling and both the S/N ratios and the sensitivity of MSD bridging assays. This result underscores the importance of optimizing the labeling of detection reagents to enhance assay sensitivity for detecting anti-AAV5 antibodies.

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-024-00970-2DOI Listing

Publication Analysis

Top Keywords

aav5 vectors
16
degree sulfo-tag
12
sulfo-tag labeling
12
binding affinity
8
bridging assay
8
assay sensitivity
8
aav vectors
8
detection reagents
8
dol sulfo-tag
8
anti-aav5 monoclonal
8

Similar Publications

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period.

View Article and Find Full Text PDF
Article Synopsis
  • Adeno-associated virus (AAV)-based gene therapy aims to treat hereditary disorders by replacing faulty genes, but the challenge is that many of these genes are larger than AAV's 5 kilobase capacity.
  • Researchers are exploring strategies like truncated gene versions and intein-based protein trans splicing to restore full gene functionality, focusing on the effectiveness of different inteins from the DnaE group.
  • The NpuDnaE variant has shown promising results, achieving 80% GFP assembly in HEK293 cells, indicating potential for higher efficiency in gene therapy applications.
View Article and Find Full Text PDF

We conducted a genome-wide CRISPR/Cas9 screen in suspension 293 F cells transduced with rAAV5. The highly selected genes revealed after two rounds of screening included the previously reported , , and , along with a cluster of genes involved in glycan biogenesis, Golgi apparatus localization, and endoplasmic reticulum penetration. In this report, we focused on solute carrier family 35 member A1 (), a Golgi apparatus-localized cytidine 5'-monophosphate-sialic acid (CMP-SIA) transporter.

View Article and Find Full Text PDF

Tropism of adeno-associated virus serotypes in mouse lungs via intratracheal instillation.

Virol J

November 2024

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Background: Gene therapy holds great potential for treating various acquired and inherited pulmonary diseases. Adeno-associated viral (AAV) vectors have been thought to be primary candidates for gene delivery in patients with pulmonary diseases. However, the tropism of AAVs in the lungs remains largely unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory Syncytial Virus (RSV) causes respiratory illness primarily in infants and the elderly, with limited preventive measures available, prompting interest in using adeno-associated virus (AAV) for vaccine development.
  • The study tested a recombinant AAV5 (rAAV5) vaccine targeting the pre-fusion protein of RSV, administering it intramuscularly and intranasally in mice to evaluate its immunogenicity.
  • Results showed that the rAAV5-RSV-Fm vaccine produced strong antibody responses against RSV strains A and B for 120 days, with intranasal delivery also generating protective antibodies, indicating rAAV5's promise in RSV vaccine development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!